Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chart: Numbers Don't Lie: Update on Citations of False and Misleading Advertising

Executive Summary

It's panning out to be a big year for advertising enforcement. The FDA Amendments Act infused new resources and authority into FDA's Division Drug Marketing, Advertising and Communication, allowing DDMAC to beef-up its operations and put more attention and resources into advertising enforcement ("The Pink Sheet," May 25, 2009, p. 3). Speaking at a June 22 session of the Drug Information Association annual meeting in San Diego, DDMAC Director Thomas Abrams gave an update of the division and its enforcement actions from June 2008 through May 2009.
Advertisement

Related Content

FDA Ad Enforcement Steams On; Are “Days Of Pushing The Envelope” Over?

Topics

Advertisement
UsernamePublicRestriction

Register

PS051235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel